Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bone graft & orthobiologics cases in Texas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 12% on average (190 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 82 | 3,503 | 44% |
| 2020 | 70 | 3,087 | 47% |
| 2021 | 69 | 2,994 | 51% |
| 2022 | 63 | 2,899 | 54% |
| 2023 | 56 | 2,491 | 57% |
| 2024 | 52 | 1,980 | 59% |
| 2025 from claims | – | 1,813 1,664–1,918 | 59% |
| 2026 forecast | – | 1,844 1,622–2,128 | 60% |
| 2027 forecast | – | 1,873 1,601–2,232 | 60% |
| 2028 forecast | – | 1,903 1,588–2,330 | 61% |
| 2029 forecast | – | 1,933 1,579–2,424 | 61% |
| 2030 forecast | – | 1,963 1,573–2,516 | 62% |
Graft add-on codes identify surgeons using biologics across spine and extremity cases. Professional codes (what the surgeon bills): CPT 20930, 20931, 20936, 20937, 20938, 20939.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 40% of the cases CMS names in Texas; 32 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 80% inpatient hospital, 18% hospital outpatient, 3% surgery center. The share outside the hospital has moved +2 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 34 | 1,353−8.3%/yr | −8.3%/yr | 0.6 | 6% | 1,490 in 2030+1.6%/yr |
| Georgia | 15 | 773−3.8%/yr | −3.8%/yr | 0.9 | 5% | 720 in 2030−1.3%/yr |
| Virginia | 17 | 601−14%/yr | −14%/yr | 0.6 | 0% | 650 in 2030+1.2%/yr |
| North Carolina | 14 | 525−14%/yr | −14%/yr | 0.5 | 2% | 520 in 2030−0.2%/yr |
| Tennessee | 16 | 498−9.2%/yr | −9.2%/yr | 0.7 | 3% | 450 in 2030−1.8%/yr |
| Arkansas | 8 | 484−8.7%/yr | −8.7%/yr | 1.2 | 2% | 370 in 2030−4.3%/yr |
| Maryland | 14 | 451−8%/yr | −8%/yr | 0.5 | 4% | 370 in 2030−3.3%/yr |
| South Carolina | 13 | 440−13%/yr | −13%/yr | 0.6 | 1% | 450 in 2030+0.5%/yr |
| Oklahoma | 13 | 397−18%/yr | −18%/yr | 0.8 | 1% | 430 in 2030+1.3%/yr |
| Louisiana | 8 | 369−1.6%/yr | −1.6%/yr | 0.9 | 1% | 360 in 2030−0.5%/yr |
| Delaware | 7 | 334−2.8%/yr | −2.8%/yr | 1.9 | 11% | 340 in 2030+0.5%/yr |
| Alabama | 10 | 293−20%/yr | −20%/yr | 0.6 | 4% | 290 in 20300%/yr |
| Kentucky | 7 | 228−18%/yr | −18%/yr | 0.5 | 0% | 260 in 2030+2.1%/yr |
| Mississippi | 5 | 119−17%/yr | −17%/yr | 0.3 | 11% | 90 in 2030−4.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 1,025 | 283,370+3.6%/yr | +3.6%/yr | 125.01.1× | 51% | 394,700 in 2030+5.7%/yr |
| Skin substitutes & wound grafts | 193 | 48,756+22%/yr | +22%/yr | 13.21.3× | 77% | 79,300 in 2030+8.4%/yr |
Bone graft & orthobiologics in every state, and its device makers · Every procedure market in Texas · Every state · Compare with Florida
Bausch & Lomb leads with 31% of company spending on these surgeons in 2025, −10 pts on 2024.
In 2025, 17 companies reported engagement with Texas’s surgeons worth $469K in consulting, speaking, meals and travel tied to these products, about $9,010 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.